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>48cc group was 90% vs 46% (chi square p =.001). ROC curve 
analysis of our oropharyngeal subgroup revealed similar 
results with a cut off of 48cc with AUC of 0.802 (0.677-0.927) 
and sensitivity / specificity of 86%/70%.The RR for the <48cc 
and >48cc group was 88% vs 40% (chi square p =.001). The 
likelihood of not responding increased by 1.8%% for 1cc 
increase in TTV for the entire cohort and by 2.4% for our 
oropharyngeal subgroup. 
 
 
 
 
Conclusion: Our study shows that the TTV is a significant and 
independent prognostic factor in patients with locally 
advanced head and neck cancer in terms of predicting local 
control. Implications for existing management paradigms 
include, stratification according to TTV in future randomized 
trials and consideration of altered fractionation and/or dose 
escalation to the primary disease for patients with TTV>48cc.  
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Purpose or Objective: To evaluate the prognostic value of 
18F-FDG PET-CT performed prior to (prePET) and during the 
third week (iPET) of radiation therapy (RT) in patients with 
newly diagnosed nasopharyngeal carcinoma (NPC). 
 
Material and Methods: Thirty patients with newly diagnosed 
NPC treated with radical RT and Cisplatin-based 
chemotherapy underwent prePET and iPET. The median 
follow up was 26 months (range 8-66.9). AJCC staging 
included 12 patients in stage II, 8 in stage III and 10 in stage 
IV. The maximum standardised-uptake-value (SUVmax), 
metabolic-tumour-volume (MTV) and total-lesional-glycolysis 
(TLG) of primary tumour (PT), the index-node (IN) (defined as 
lymph node with highest TLG), total lymph nodes (TN) and 
combined primary tumour and nodal (PTN), and their % 
reductions in iPET were analysed, and results were correlated 
with 2-year loco-recurrence-free-survival (LRFS), regional-
failure-free-survival (RFFS), distant-metastatic-failure-free-
survival (DMFFS), disease-free-survival (DFS), and overall-
survival (OS), using Kaplan-Meier (KM) analysis. Optimal-
cutoffs (OC) were derived from Receiver-Operating-
Characteristic curves for the best combined sensitivity and 
specificity. 
 
Results: For LRFS, the only statistically significant predictor 
was reduction in primary tumour MTV by >50% in iPET (95.2% 
vs 75.0%, p=0.024). For other treatment outcomes, only 
nodal or combined PTN predicted treatment outcomes. The 
IN SUVmax (pre-PET OC=10.45g/mL and iPET OC=8.15g/mL) 
and TLG (pre-PET OC=90g and iPET OC=33.4g) provide the 
overall best predictor of outcome, with significant 
associations with RFFS (iPET only), DMFFS (prePET), DFS 
(prePET and iPET) and OS (prePET): For RFFS, iPET IN 
SUVmax and TLG were best predictors: the 2-year KM 
survivals were 100% vs. 50%, p<0.001 and 100% vs. 44%, 
p=0.032 respectively. For DMFFS, prePET IN SUVmax and TLG 
were best predictors: 100% vs. 51.9%, p=0.004 and 100% vs. 
47.6%, p=0.002. For DFS, prePET IN TLG and iPET IN SUVmax 
were best predictors: 87.5% vs. 33%, p=0.045 and 78.7% vs. 
20%, p=0.01. For OS, prePET IN TLG and iPET IN TLG were 
best predictors: 100% vs 72.7%, p=0.048 and 91.7% vs 68.6%, 
p=0.05. The IN metabolic parameters demonstrated stronger 
correlation with outcome than PT or PTN, and equivalent 
correlation to the TN except IN was better in predicting OS. 
 
Conclusion: The metabolic parameters of prePET and iPET 
can provide complementary prognostic biomarkers of patient 
outcomes, These parameters may have a role in adaptive 
therapy for NPC, and identifying the best treatment strategy 
for precision individualised chemo-radiotherapy 
combinations. We have demonstrated IN to be a useful novel 
imaging biomarker for predicting all treatment outcomes, 
and offers additional potential advantage of ease of 
generation and reproducibility compared to TN or PTN. 
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Purpose or Objective: Statistical image features from 
computed tomography (CT) and positron emission 
tomography (PET) scans are being investigated for the 
potential prognostic value in predicting outcome for various 
clinical indications. Here, we analyze primary tumor image 
features from pretreatment FDG-PET and the relation to 
clinical outcomes in patients treated with definitive radiation 
therapy (RT) for laryngeal cancer. 
 
Material and Methods: We identified 83 consecutive patients 
with laryngeal squamous cell carcinoma treated with 
definitive RT with available pretreatment PET/CT scans at 
our institution. Clinical variables related to disease and 
patient characteristics, treatment information, and clinical 
outcomes data were collected for each patient. Pretreatment 
PET/CT scans were used for image feature analysis of the 
primary tumor volume for each patient. Multiple statistical 
image features were computed, along with several measures 
related to the standardized uptake value (SUV). Redundant 
image features were excluded based on a strong correlation 
with parameters commonly reported as important such as 
metabolic tumor volume (MTV) and maximum SUV value 
(SUVmax). A LASSO procedure was applied to select 
appropriate variables to include in Cox proportional hazard 
models for local control (LC) progression-free survival (PFS) 
and overall survival (OS). The concordance index or “C-
index” was computed to evaluate the discriminative ability of 
each model, both on the training data set (apparent C-index) 
and using bootstrap cross-validation (bCV). Correction for 
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multiple testing in statistical analysis was done using the 
Benjamini-Hochberg method. 
 
Results: With a median follow up of 34 months, the 3-year 
LC, PFS and OS (with 95% confidence intervals) were 64% (53% 
- 75%), 51% (39% - 62%) and 77% (67% - 87%), respectively. No 
image features were significantly correlated with LC or PFS 
and adding image features to the clinical variables did not 
improve the performance of the Cox model in the bCV 
setting, as seen in Table 1 where the C-index is highlighted in 
bold if adding image features improved performance.  
 
 
 
MTV was the image feature most closely related to OS and for 
OS the addition of image features did improve the predictive 
performance of the Cox model. Figure 1 shows the effect of 
dividing the patient population based on the statistically 
most important variables, where it is clear that Karnofsky 
performance score and MTV affect the OS. 
 
 
Conclusion 
Adding image features to complement clinical parameters 
was seen to improve the prognostic value for OS. Although no 
significant image features were found related to LC and PFS, 
we found that a smaller MTV was predictive of improved OS. 
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Purpose or Objective: Among cancers of head and neck, 
hypopharyngeal cancers tend to have an aggressive clinical 
course. Chemoradiation has become the standard of care for 
patients who are candidates for an organ preservation 
strategy. IMRT planning has incorporated a simultaneous 
integrated boost (SIB-IMRT) in order to efficiently develop 
comprehensive radiation therapy plans and also potentially 
lessen treatment time and toxicity. Outcomes and toxicites 
of patients with hypopharyngeal cancers treated in a single 
institute with standard IMRT and SIB-IMRT schedules were 
analyzed retrospectively. 
 
Material and Methods: A total of 86 patients with 
hypopharyngeal squamous cell carcinomas were treated 
between September 2010 and December 2014. Among 44 
patients who were treated using SIB-IMRT, 8 received 
neoadjuvant chemotherapy (NACT) and 42 received 
concurrent chemotherapy. Among 42 patients who were 
treated using IMRT with conventional fractionation (IMRT),16 
received NACT and 40 received concurrent chemotherapy. 
The dose for SIB-IMRT group was 65 Gy in 30 fractions to gross 
and high risk disease and 54 Gy in 30 fractions to low-risk 
nodes. The dose in IMRT group was 66-70 Gy to gross disease, 
60 Gy to high risk nodes and 50 Gy to low risk nodes in 1.8-2 
Gy per fraction. 
 
Results: At a median follow-up of 16.5 months (6-56 months) 
the median OS of entire cohort was 38.9 months. The mean 
OS was 37.5 months and 38.3 months (p=0.91) for SIB-IMRT 
and IMRT respectively. The mean treatment duration for SIB-
IMRT and IMRT groups was 42 days (range: 38-51 days) and 
48.4 days (range: 45-73 days) respectively. 98 % in SIB-IMRT 
and 93 % patients in IMRT group completed the intended 
treatment. Complete response was noted in 89 % and 93 % in 
SIB-IMRT and IMRT groups respectively. The estimated 1 year, 
2 year LR control and 2-year DFS were 81%, 66.6%, 67.4% in 
SIB-IMRT and 84%, 74%, 62% (p<0.81) in IMRT groups 
respectively.Grade 3 mucositis occurred in 10 (23%) and 12 
(28%), grade 3 dermatitis in 9 (20.5%) and 12 (28%) of SIB-
IMRT and IMRT patients respectively. Grade 2 xerostomia 
occurred in 11 patients (27%) and 15 patients (34%) in IMRT 
and SIB-IMRT groups. Grade 3 soft-tissue fibrosis and 
esophageal stricture rates were 2 (4.7 %) and 5 (11.4%) in SIB-
IMRT and IMRT groups. 
 
 
 
Conclusion: Clinical outcomes, acute and late toxicities of 
chemo-radiation with SIB-IMRT were comparable with IMRT. 
Overall treatment duration was reduced and more patients 
completed intended treatment in SIB-IMRT group with 
relatively lesser acute toxicities. 
 
EP-1098  
Radiation induced brachial plexopathy in head and neck 
carcinoma (acute and chronic) 
S. Yahya
1Hall-Edwards Radiotherapy Research Group- Queen 
Elizabeth Hospital, Cancer Center, Birmingham, United 
Kingdom 
1, M. Hickman1, A. Hartley1, P. Sanghera1 
 
Purpose or Objective: Radiation Therapy Oncology Group 
(RTOG) guidelines recommend brachial plexus dose 
constraints ranging from 60-66Gy in 2Gy per fraction (BED = 
120-132Gy2). However there remains limited data on brachial 
plexus (BR.P) toxicity and furthermore the dose limits are 
